Docking-enabled pharmacophore model for histone deacetylase 8 inhibitors and its application in anti-cancer drug discovery.

Zinc-dependent histone deacetylase 8 removes the epsilon-acetyl groups present in the N-terminal lysine residues of histone proteins, thereby restricting various transcription factors from being expressed. Inhibition of this enzyme has been reported to be a novel strategy in cancer treatment. To identify novel and diverse leads for use in potent histone deacetylase 8 inhibitor design, a pharmacophore model showing high correlation between experimental and estimated activities was generated using the best conformations of training set compounds from molecular docking experiments. The best pharmacophore model was validated using four different strategies and then used in database screening for novel virtual leads. Hit compounds were selected and subjected to molecular docking using GOLD. The top-scored compound was further optimized for improved binding. The optimization step led to a new set of compounds with both improved binding at the active site and estimated activities. The identified virtual leads could be used for designing potent histone deacetylase 8 inhibitors as anti-cancer therapeutics.

[1]  N. L. La Thangue,et al.  HDAC inhibitor-based therapies and haematological malignancy. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  M. Binaschi,et al.  Histone deacetylase inhibitors: from bench to clinic. , 2008, Journal of medicinal chemistry.

[3]  S. Tachiiri,et al.  Role of NAD‐dependent deacetylases SIRT1 and SIRT2 in radiation and cisplatin‐induced cell death in vertebrate cells , 2005, Genes to cells : devoted to molecular & cellular mechanisms.

[4]  Ronald Breslow,et al.  Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug , 2007, Nature Biotechnology.

[5]  Jianpeng Ma,et al.  Molecular docking study of the interactions between the thioesterase domain of human fatty acid synthase and its ligands , 2008, Proteins.

[6]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[7]  E. Seto,et al.  Phosphorus-based SAHA analogues as histone deacetylase inhibitors. , 2003, Organic letters.

[8]  Evan Bolton,et al.  An overview of the PubChem BioAssay resource , 2009, Nucleic Acids Res..

[9]  Christopher B. Harrison,et al.  Structural origin of selectivity in class II-selective histone deacetylase inhibitors. , 2008, Journal of medicinal chemistry.

[10]  C. Horvath,et al.  Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: Potent inhibition of histone deacetylases. , 2006, Bioorganic & medicinal chemistry.

[11]  R. De Francesco,et al.  Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8–substrate complex , 2007, EMBO reports.

[12]  Tao Liu,et al.  Design and synthesis of a potent histone deacetylase inhibitor. , 2007, Journal of medicinal chemistry.

[13]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[14]  Bin Chen,et al.  Functional differences in epigenetic modulators-superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies. , 2007, Journal of medicinal chemistry.

[15]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[16]  C L Brooks,et al.  Do active site conformations of small ligands correspond to low free-energy solution structures? , 1998, Journal of computer-aided molecular design.

[17]  J. R. Somoza,et al.  Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. , 2004, Structure.

[18]  Barbara Hero,et al.  Histone Deacetylase 8 in Neuroblastoma Tumorigenesis , 2009, Clinical Cancer Research.

[19]  Johann Gasteiger,et al.  Structure and reaction based evaluation of synthetic accessibility , 2007, J. Comput. Aided Mol. Des..

[20]  Jonas Boström,et al.  Reproducing the conformations of protein-bound ligands: A critical evaluation of several popular conformational searching tools , 2001, J. Comput. Aided Mol. Des..

[21]  Kavitha Bharatham,et al.  Pharmacophore identification and virtual screening for methionyl-tRNA synthetase inhibitors. , 2007, Journal of molecular graphics & modelling.

[22]  M. Parthun,et al.  Properties of the Type B Histone Acetyltransferase Hat1 , 2007, Journal of Biological Chemistry.

[23]  O. Moradei,et al.  Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. , 2007, Journal of medicinal chemistry.

[24]  C. Monneret,et al.  Histone deacetylase inhibitors. , 2005, European journal of medicinal chemistry.

[25]  Silvio Massa,et al.  Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation. , 2002, Journal of medicinal chemistry.

[26]  T. Kummalue,et al.  The inv(16) Fusion Protein Associates with Corepressors via a Smooth Muscle Myosin Heavy-Chain Domain , 2003, Molecular and Cellular Biology.

[27]  M. Bottomley,et al.  2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[28]  G. Brodeur.  Neuroblastoma: biological insights into a clinical enigma , 2003, Nature Reviews Cancer.

[29]  C. Fierke,et al.  Structural studies of human histone deacetylase 8 and its site-specific variants complexed with substrate and inhibitors. , 2008, Biochemistry.

[30]  P. Marks,et al.  Histone Deacetylase Inhibitors: Overview and Perspectives , 2007, Molecular Cancer Research.

[31]  Thierry Langer,et al.  Comparative Analysis of Protein-Bound Ligand Conformations with Respect to Catalyst's Conformational Space Subsampling Algorithms , 2005, J. Chem. Inf. Model..

[32]  P. Schultz,et al.  Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group. , 2004, Bioorganic & medicinal chemistry letters.

[33]  A. Kozikowski,et al.  A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum. , 2008, Journal of medicinal chemistry.

[34]  Yong-Jun Jiang,et al.  Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling. , 2008, Journal of molecular graphics & modelling.

[35]  T. Langer,et al.  Pharmacophore definition and 3D searches. , 2004, Drug discovery today. Technologies.

[36]  P. Marks,et al.  Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.

[37]  S. Minucci,et al.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.

[38]  D. Koshland,et al.  EVIDENCE FOR CONFORMATION CHANGES INDUCED BY SUBSTRATES OF PHOSPHOGLUCOMUTASE. , 1965, The Journal of biological chemistry.

[39]  René Thomsen,et al.  MolDock: a new technique for high-accuracy molecular docking. , 2006, Journal of medicinal chemistry.

[40]  Holger Claussen,et al.  Second-generation de novo design: a view from a medicinal chemist perspective , 2009, J. Comput. Aided Mol. Des..

[41]  W. Sippl,et al.  Histone deacetylase inhibitors that target tubulin. , 2009, Cancer letters.

[42]  Thierry Langer,et al.  Pharmacophore Modeling and in Silico Screening for New P450 19 (Aromatase) Inhibitors , 2006, J. Chem. Inf. Model..

[43]  P. Marks,et al.  Histone deacetylase inhibitors: molecular mechanisms of action , 2007, Oncogene.

[44]  W-S Xu,et al.  Histone deacetylase inhibitors: Potential in cancer therapy , 2009, Journal of cellular biochemistry.

[45]  M. Neves,et al.  An efficient steroid pharmacophore-based strategy to identify new aromatase inhibitors. , 2009, European journal of medicinal chemistry.

[46]  Richard D. Taylor,et al.  Improved protein–ligand docking using GOLD , 2003, Proteins.

[47]  Yadong Chen,et al.  Pharmacophore Identification of Hydroxamate HDAC 1 Inhibitors , 2009 .

[48]  Kyle V. Butler,et al.  Chemical origins of isoform selectivity in histone deacetylase inhibitors. , 2008, Current pharmaceutical design.

[49]  A. Ben Wagner,et al.  SciFinder Scholar 2006: An Empirical Analysis of Research Topic Query Processing , 2006, J. Chem. Inf. Model..

[50]  S. Vadivelan,et al.  Pharmacophore modeling and virtual screening studies to design some potential histone deacetylase inhibitors as new leads. , 2008, Journal of molecular graphics & modelling.